

SANOFI-AVENTIS  
Form 6-K  
September 11, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of September 2007**

**Commission File Number: 001-31368**

---

**SANOFI-AVENTIS**

**(Translation of registrant's name into English)**

---

**174, avenue de France, 75013 Paris, FRANCE**

**(Address of principal executive offices)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Yes  No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

In September 2007, sanofi-aventis issued the press releases attached hereto as Exhibit 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

**Exhibit List**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated September 2 <sup>nd</sup> , 2007: New study findings confirm CLEXANE <sup>®</sup> /LOVENOX <sup>®</sup> long-term clinical benefit in patients suffering from acute coronary syndrome.
Exhibit 99.2	Press release dated September 4, 2007: Survival benefit of Taxotere <sup>®</sup> - Based regimens in patients with non small cell lung cancer.
Exhibit 99.3	Press release dated September 5, 2007: The New England Journal of Medicine publishes EURIDIS/ADONIS study results showing dronedarone maintained sinus rhythm in patients with atrial fibrillation or flutter with no observed pro-arrhythmia.
Exhibit 99.4	Press release dated September 10, 2007: Sanofi-Aventis announces settlement of average wholesale price civil suits with the U.S. department of justice relating to Anzemet.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 10, 2007

SANOFI-AVENTIS

By /S/ Patricia Kodyra  
Name: Patricia Kodyra  
Title: Associate Vice President  
Financial and Securities Law

**Exhibit Index**

<b>Exhibit No.</b>	<b>Description</b>
Exhibit 99.1	Press release dated September 2 <sup>nd</sup> , 2007: New study findings confirm CLEXANE®/LOVENOX® long-term clinical benefit in patients suffering from acute coronary syndrome.
Exhibit 99.2	Press release dated September 4, 2007: Survival benefit of Taxotere®- Based regimens in patients with non small cell lung cancer.
Exhibit 99.3	Press release dated September 5, 2007: The New England Journal of Medicine publishes EURIDIS/ADONIS study results showing dronedarone maintained sinus rhythm in patients with atrial fibrillation or flutter with no observed pro-arrhythmia.
Exhibit 99.4	Press release dated September 10, 2007: Sanofi-Aventis announces settlement of average wholesale price civil suits with the U.S. department of justice relating to Anzemet.